Liquidia Corporation LQDA
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, primarily in the United States. The company develops, manufactures, and commercializes treatments aimed at addressing unmet patient needs in pulmonary hypertension. Its key product, Yutrepia, is an inhaled dry po…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees170
TickerLQDA
Statistics
Market Cap$6.05B
Revenue (TTM)$158.3M
Net Income-$68.9M
Net Margin-43.5%
EPS$-0.80
P/E386.24
P/S20.27
P/B53.38
EV/EBITDA121.27
ROE28.2%
Dividend Yield—
Price$68.52
Data: Twelve Data · Revenue = mcap / P/S